Dr Xiangjian Zheng: Tyrosine kinase inhibitor active against cerebral cavernous malformations

Ponatinib dials down the hyperactive signalling pathway of the enzyme MEKK3 associated with mutations in cerebral cavernous malformation (CCM) genes. The pre-clinical research opens up the potential for a treatment to prevent CCM initiation or progression and reduce the risk of sequelae such as stroke and neurological deficits. The limbic asked Dr Xiangjian Zheng, head ...

Already a member?

Login to keep reading.

© 2021 the limbic